Loading clinical trials...
Loading clinical trials...
A Phase 2, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of NGM120 in Participants With Colorectal Cancer Who Have Cancer Cachexia
A multi-center evaluation of NGM120 in a randomized, double-blind, placebo-controlled study in participants with colorectal cancer who have cancer cachexia.
Evaluation of Efficacy, Safety and Tolerability of NGM120 in a Phase 2, Randomized, Double-blind, Placebo-controlled, Multi-center Study in Participants with Colorectal Cancer who have Cancer Cachexia
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
NGM Clinical Study Site
Laredo, Texas, United States
Start Date
June 1, 2025
Primary Completion Date
April 1, 2027
Completion Date
December 1, 2027
Last Updated
June 27, 2025
136
ESTIMATED participants
NGM120 Q4W
DRUG
NGM120 Q8W
DRUG
Placebo given
DRUG
Lead Sponsor
NGM Biopharmaceuticals, Inc
NCT04704661
NCT06696768
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions